Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 1:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 173 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Physiological Effect of Drugs Clear all
Terminated Phase 1 Interventional

Natural Killer Cell (CYNK-001) Infusions in Adults with AML

NCT04310592
View directory record Official record
Conditions
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasms by Histologic Type, Neoplasms, Immunosuppressive Agents, Immunologic Factors, Physiological Effects of Drugs, Alkylating Agents, Antimetabolites, Antineoplastic, Antiviral Agents, Analgesics, Non-narcotic, Anti-infective Agents, Analgesics, Peripheral Nervous System Agents, Hematologic Diseases, Hematologic Neoplasms, Leukemia in Remission, Relapsed Adult AML, Refractory AML
Interventions
CYNK-001
Biological
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Denver, Colorado • Chicago, Illinois • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 9, 2026, 1:14 AM EDT
Completed Phase 1 Interventional

Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma

NCT02010606
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme, Glioma, Astrocytoma, Brain Tumor
Interventions
Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy, Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab
Biological
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Oct 9, 2026, 1:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of Abdominal Wall Block With Liposomal Bupivacaine for Post-Operative Analgesia in Donor Nephrectomy

NCT03294109
View directory record Official record
Conditions
Pain, Postoperative, Analgesics, Opioid, Analgesics, Non-Narcotic, Physiological Effects of Drugs, Peripheral Nervous System Agents, Patient Satisfaction, Return to Work, Activity, Sexual
Interventions
Abdominal wall block with liposomal bupivicaine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 9, 2026, 1:14 AM EDT
Completed Phase 3 Interventional

A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)

NCT06584916
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
27
States / cities
Birmingham, Alabama • Pelham, Alabama • Santa Ana, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 9, 2026, 1:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans

NCT04032301
View directory record Official record
Conditions
Post-Traumatic Stress Disorders, Major Depressive Disorder
Interventions
Ketamine, Normal Saline
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 9, 2026, 1:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effects of Smell on Mood and Physical Responses

NCT00097253
View directory record Official record
Conditions
Stress, Anxiety, Depression
Interventions
Exposure to relaxant and stimulant odors
Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 44 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 18, 2010 · Synced Oct 9, 2026, 1:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective

NCT01754987
View directory record Official record
Conditions
Metastatic Hepatocellular Carcinoma, Advanced Liver Cancer
Interventions
Ascorbic Acid + Sorafenib, Sorafenib
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 9, 2026, 1:14 AM EDT
Completed Phase 4 Interventional

Memantine for Corticosteroid-Induced Mood and Declarative Memory Changes

NCT00280774
View directory record Official record
Conditions
Physiological Effects of Drugs
Interventions
Memantine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2008 · Synced Oct 9, 2026, 1:14 AM EDT
Not listed Phase 3 Interventional

Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors

NCT01204801
View directory record Official record
Conditions
Breast Cancer
Interventions
Focused Microwave Thermotherapy, Chemotherapy (control)
Device · Drug
Lead sponsor
Medifocus, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 9, 2026, 1:14 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Behavior Brain Responses

NCT03964350
View directory record Official record
Conditions
Alcohol Drinking, Drinking Behavior, Physiological Effects of Drugs, Central Nervous System Depression
Interventions
Ethanol, Placebo
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 35 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 9, 2026, 1:14 AM EDT
Terminated Phase 2 Interventional Results available

SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma

NCT00365274
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma
Interventions
Cyclophosphamide, Doxorubicin hydrochloride, vincristine sulfate, prednisone, SGN-30
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Oct 9, 2026, 1:14 AM EDT
Completed Phase 4 Interventional Results available

Effect of Low Dose Corticosteroids on Perioperative Markers of Thrombosis and Fibrinolysis in Total Knee Arthroplasty

NCT01815918
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Hydrocortisone, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
50 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 9, 2026, 1:14 AM EDT
Active, not recruiting Phase 3 Interventional

An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia

NCT03424018
View directory record Official record
Conditions
Achondroplasia
Interventions
BMN 111
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
6 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
11
States / cities
Oakland, California • Torrance, California • Wilmington, Delaware + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 9, 2026, 1:14 AM EDT
Terminated Phase 4 Interventional Results available

Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure

NCT04071626
View directory record Official record
Conditions
Heart Failure, Diastolic, Diabetes Mellitus, Type 2
Interventions
Ertugliflozin 5 mg, Placebo oral tablet
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 9, 2026, 1:14 AM EDT
Active, not recruiting Phase 3 Interventional

Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia

NCT06455059
View directory record Official record
Conditions
Hypochondroplasia
Interventions
Vosoritide, Placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
3 Years to 17 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Wilmington, Delaware • Washington D.C., District of Columbia • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 9, 2026, 1:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex

NCT05794503
View directory record Official record
Conditions
Urinary Retention Postoperative, Laparoscopic Cholecystectomy, Neuromuscular Blockade, Sugammadex, Neostigmine, Neuromuscular Blocking Agents, Physiological Effects of Drugs
Interventions
Neostigmine, Sugammadex
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 9, 2026, 1:14 AM EDT
Completed Phase 2 Interventional Results available

Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder

NCT02909959
View directory record Official record
Conditions
Autism Spectrum Disorder, Autistic Disorder, Neurodevelopmental Disorder, Childhood Developmental Disorders, Pervasive
Interventions
Sulforaphane, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
13 Years to 30 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Carrboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 9, 2026, 1:14 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

NCT01008423
View directory record Official record
Conditions
Proctitis, Proctosigmoiditis
Interventions
Budesonide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
62
States / cities
Dothan, Alabama • Mesa, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 9, 2026, 1:14 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers Results available

A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants

NCT05217641
View directory record Official record
Conditions
HIV Infections
Interventions
BG505 MD39.3 mRNA, BG505 MD39.3 gp151 mRNA, BG505 MD39.3 gp151 CD4KO mRNA
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 9, 2026, 1:14 AM EDT
Completed Phase 1Phase 2 Interventional

A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors

NCT00841191
View directory record Official record
Conditions
Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms
Interventions
CNTO 328; Anti-interleukin-6 monoclonal antibody
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 9, 2026, 1:14 AM EDT
Completed Phase 2 Interventional Results available

A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis

NCT01610596
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Halobetasol Propionate Lotion 0.05%, Placebo
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
San Diego, California • Fridley, Minnesota • Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2016 · Synced Oct 9, 2026, 1:14 AM EDT
Completed Phase 2 Interventional Results available

Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent

NCT01681095
View directory record Official record
Conditions
Coronary Artery Disease, Myocardial Ischemia, Coronary Disease, Heart Diseases, Valvular Heart Disease
Interventions
Custodiol HTK, Cold Blood Cardioplegia
Drug
Lead sponsor
Marc Sakwa, MD
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 9, 2026, 1:14 AM EDT
Recruiting Phase 2 Interventional

Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder

NCT05999240
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID], Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
12 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Lawrence, Kansas • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 9, 2026, 1:14 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

NCT04365101
View directory record Official record
Conditions
Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2, Pneumonia, Pneumonia, Viral, Lung Diseases, Respiratory Tract Disease, Respiratory Tract Infections, Coronaviridae Infections, Nidovirales Infections, RNA Virus Infections, Virus Disease, Immunologic Disease, ARDS, Immunologic Factors, Physiological Effects of Drugs, Antiviral Agents, Anti-infective Agents, Analgesics, Antimetabolites, Antineoplastic
Interventions
CYNK-001
Biological
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Irvine, California • Morristown, New Jersey • Summit, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 9, 2026, 1:14 AM EDT